Core Viewpoint - Eesti Energia is set to publish its 2025 financial results and interim report on 27 February, with an investor call scheduled for the same day to discuss the results [1] Group 1: Financial Results Announcement - The financial results and interim report will be released on 27 February [1] - The investor call will occur at 11:00 London time, 12:00 Frankfurt time, and 13:00 Tallinn time [1] - The presentation will be conducted in English, followed by a Q&A session [1] Group 2: Participation and Access - Participants are encouraged to submit questions in advance via email to ensure a productive Q&A session [1] - The report and presentation will be available on the Eesti Energia Investor Relations website on the morning of 27 February [1] - A recording and transcript of the call will be published on the same website after the event [1] Group 3: Contact Information - Danel Freiberg is the Head of Treasury and Financial Risk Management at Eesti Energia AS, available for further inquiries [2] - Contact details include a phone number and email address for direct communication [2]

Core Insights - Novo Nordisk announced results from the REDEFINE 4 trial, which investigated the efficacy of CagriSema compared to tirzepatide in individuals with obesity and comorbidities [1][2] Trial Overview - REDEFINE 4 was an 84-week open-label trial involving 809 participants with a mean baseline body weight of 114.2 kg [2] - The trial compared CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) to tirzepatide (15 mg), both administered once weekly [2] Weight Loss Results - Participants treated with CagriSema achieved a weight loss of 23.0% after 84 weeks, compared to 25.5% with tirzepatide [3] - When applying the treatment-regimen estimand, CagriSema resulted in a weight loss of 20.2%, while tirzepatide achieved 23.6% [3] - The trial did not meet its primary endpoint of demonstrating non-inferiority in weight loss for CagriSema compared to tirzepatide [3] Safety Profile - CagriSema exhibited a safe and well-tolerated profile, with the most common adverse events being mild to moderate gastrointestinal issues that diminished over time [4] Future Developments - Novo Nordisk is optimistic about CagriSema's potential as a first GLP-1/amylin-combination product for obesity treatment [5] - The company anticipates an FDA decision on CagriSema for weight management by late 2026, following its submission in December 2025 [5] - Upcoming trials include REDEFINE 11, expected to report data in the first half of 2027, and a higher-dose CagriSema trial planned for the second half of 2026 [5] About CagriSema - CagriSema is a once-weekly subcutaneous treatment being investigated for adults with obesity and type 2 diabetes, combining cagrilintide and semaglutide to reduce hunger and calorie intake [7] About the REDEFINE Programme - The REDEFINE programme is a phase 3 clinical development initiative that includes multiple trials assessing the efficacy and safety of CagriSema in various populations [8][9][10][11][12]

Core Insights - Novo Nordisk announced results from the REDEFINE 4 trial, which investigated the efficacy of CagriSema compared to tirzepatide in individuals with obesity and comorbidities [1][2]. Trial Overview - REDEFINE 4 was an 84-week open-label trial involving 809 participants with a mean baseline body weight of 114.2 kg, comparing CagriSema (2.4 mg cagrilintide and 2.4 mg semaglutide) to tirzepatide (15 mg) [2]. - The trial's design was open-label, meaning both investigators and participants were aware of the treatment being administered [2]. Efficacy Results - Participants treated with CagriSema achieved a weight loss of 23.0% after 84 weeks, compared to 25.5% with tirzepatide [3]. - When applying the treatment-regimen estimand, CagriSema resulted in a weight loss of 20.2%, while tirzepatide achieved 23.6% [3]. - The trial did not meet its primary endpoint of demonstrating non-inferiority in weight loss for CagriSema compared to tirzepatide [3]. Safety Profile - CagriSema exhibited a safe and well-tolerated profile, with the most common adverse events being mild to moderate gastrointestinal issues that diminished over time [4]. Future Developments - The company is optimistic about CagriSema's potential as a first GLP-1/amylin-combination product for obesity treatment, with plans for further trials including REDEFINE 11 and a higher-dose trial [5]. - CagriSema was submitted to the US FDA in December 2025, with a decision expected by late 2026 [5]. - The REDEFINE 11 trial is anticipated to report data in the first half of 2027, while the higher-dose trial is set to begin in the second half of 2026 [5]. About CagriSema - CagriSema is a once-weekly subcutaneous treatment being investigated for adults with obesity and type 2 diabetes, combining cagrilintide and semaglutide to reduce hunger and increase feelings of fullness [7]. About the REDEFINE Programme - The REDEFINE programme is a phase 3 clinical development initiative that includes multiple trials aimed at assessing the efficacy and safety of CagriSema in various populations with obesity [8][9][10][11][12].

Group 1 - The Annual General Meeting of MT Højgaard Holding A/S is scheduled for Friday, March 20, 2026, at 3 pm [1] - The meeting will take place as a physical general meeting at Knud Højgaards Vej 7, 2860 Søborg, Denmark [1] - The notice includes the agenda and the full text of the proposed resolutions, which are attached [2]

Core Insights - Expanse Studios has officially launched its proprietary game portfolio in the Belgian regulated market, marking a significant step in its international distribution strategy [1][2] Company Overview - Expanse Studios is a B2B iGaming content provider under Golden Matrix Group Inc., specializing in various gaming formats including slots and table games, with a portfolio of 56 proprietary titles [5] - Golden Matrix Group operates globally through B2B and B2C divisions, including various online gaming platforms and competitions [6] Market Context - The Belgian online casino segment generated €455 million in gross gaming revenue (GGR) in 2023, reflecting a 20.2% year-over-year increase, indicating a robust market for online gaming [3] Strategic Drivers - Belgium is a key market for Expanse Studios due to its strict regulatory framework and high digital adoption, facilitating a transition from licensing to a revenue growth phase [4] - The launch includes over 60 certified titles tailored to meet the compliance standards of the Belgian Gaming Commission [7] - Expanse Studios achieves 100% vertical integration in Belgium by leveraging its internal B+ license, maximizing revenue-per-spin and eliminating third-party fees [7] - The integration of AI Casino Recommender technology allows for real-time analysis of player behavior, enhancing player retention and lifetime value [7] - Expanse Studios benefits from a concentrated market where 10 operators control 94% of wagers, positioning itself advantageously on the Meridianbet.be platform [7]

Core Insights - The collaboration between InterDigital and Türk Telekom marks the world's first implementation of collaborative cellular and Wi-Fi sensing using preliminary 6G architecture, to be showcased at Mobile World Congress 2026, representing a significant advancement towards intelligent 6G systems [1][7] Group 1: Collaborative Sensing Implementation - The research collaboration at Türk Telekom Innovation and Test Center demonstrates the complementary nature of cellular and Wi-Fi networks in sensing technologies, achieving improved accuracy and reduced blind spots, especially in indoor environments [2] - Integrated Sensing and Communication (ISAC) is central to this demonstration, allowing networks to communicate and sense their environment efficiently while preserving privacy [3] Group 2: Future Network Capabilities - The achievement is seen as a preview of future networks that will intelligently serve various industries, addressing challenges such as coverage gaps and resource constraints [4] - The collaboration combines InterDigital's experimental 6G sensing platform with Türk Telekom's expertise, validating continuous quality of service for sensing-enabled applications regardless of user location [4] Group 3: Potential Applications - Collaborative cellular and Wi-Fi sensing can enable applications in smart manufacturing, healthcare, and intelligent buildings, all while maintaining privacy [5][6] - The demonstration showed robust near real-time indoor human presence detection with higher accuracy than single-network sensing, validating collaborative sensing as a viable approach for future 6G systems [5] Group 4: Industry Impact - The collaboration aligns with the Wireless Broadband Alliance's efforts on Wi-Fi-cellular convergence, exploring how integrated sensing and communication can unlock new capabilities, particularly indoors [5] - Insights from this collaboration will inform future network architectures, operator strategies, and international standards as research accelerates towards 6G commercialization in the early 2030s [5]

Core Viewpoint - Spar Nord Bank A/S has approved a demerger plan to transfer part of its assets and liabilities to Kirstinehøj 17 A/S during the Extraordinary General Meeting held on 23 February 2026 [1]. Group 1: Company Actions - The shareholders of Spar Nord Bank A/S approved the proposal for a demerger in accordance with the published demerger plan [1]. - The demerger involves the transfer of specific assets and liabilities from Spar Nord Bank A/S to Kirstinehøj 17 A/S, CVR no. 31487900 [1]. Group 2: Meeting Details - The Extraordinary General Meeting took place on Monday, 23 February 2026 [1]. - The announcement was made to Nasdaq Copenhagen [1].

Core Insights - InterDigital is showcasing innovative advancements in AI, wireless, and video technologies at Mobile World Congress 2026, aimed at enhancing network and device capabilities [1][3] - The company emphasizes the integration of AI and sensing as essential components for next-generation networks and immersive video experiences [2][3] Company Innovations - InterDigital will demonstrate AI-enabled teleoperation, where remote vehicle operators utilize real-time video and AI agents to navigate complex environments [6] - The company will reveal the world's first implementation of collaborative sensing using preliminary 6G architecture, which combines data from cellular and Wi-Fi signals for real-time applications [6] - InterDigital is leading research on technologies that will expand network capacity and improve user experience in the 5G-Advanced and 6G era [6] Industry Engagement - InterDigital is participating in various industry events at MWC, including the AI Telco Troubleshooting Challenge, which invites teams to develop AI models for more resilient networks [6] - The company will engage in high-level discussions on 6G with industry leaders from North America, Europe, and Asia to foster global alignment [6] - InterDigital is also involved in shaping the path to 6G through roundtable discussions with leaders from industry, standards, and academia [6]

Core Viewpoint - Festi has been actively engaging in a share buyback program, increasing its ownership of own shares in accordance with regulatory frameworks [1][2]. Group 1: Share Buyback Details - In week 8 of 2026, Festi purchased a total of 195,000 own shares for 65,645,000 ISK, with individual purchases made on February 16, 17, 18, and 19, 2026 [1]. - The share prices for the purchases ranged from 333 ISK to 342 ISK per share, with the total amounts spent on each day being 24,975,000 ISK, 16,800,000 ISK, 11,970,000 ISK, and 11,900,000 ISK respectively [1]. - Prior to these purchases, Festi held 4,570,000 own shares, representing 1.46% of issued shares, and after the buyback, it now holds 4,765,000 own shares, or 1.52% of issued shares [2]. Group 2: Buyback Program Overview - The buyback program was initially announced on December 3, 2025, and aims to repurchase a total of 2,500,000 own shares, which is 0.80% of the issued shares, with a maximum purchase price cap of 825 million ISK [2]. - The execution of the buyback program complies with the Act on Public Limited Companies and relevant European regulations regarding market abuse and fraud [1].

Core Viewpoint - Nordea Invest has requested a temporary suspension of all its departments from Nasdaq Copenhagen due to technical challenges [1] Group 1 - The suspension will be lifted as soon as the technical issues are resolved [1]